However, with the accumulation of clinical studies, SGLT-2 inhibitors have shown remarkable renal and cardiovascular protective effects in non-diabetic CKD patients, significantly expanding their clinical applications and value (7). The gene discussed is SLC5A2; the disease is chronic kidney disease.